Call for Abstract

7th International Conference on Dementia & Care Practice, will be organized around the theme “Discernment Into Innovative Research and Care Practice Approaches Towards Dementia”

Dementia Care 2017 is comprised of 15 tracks and 143 sessions designed to offer comprehensive sessions that address current issues in Dementia Care 2017.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Alzheimer's is a kind of dementia that causes dilemma with memory, thinking and behaviour. This mainly happens due to the disruptions caused in nerve cells within the brain. The brains of individuals with Alzheimer disease have an abundance of 2 abnormal structures: amyloid plaques and neurofibrillary tangles that are product of misfolded proteins. This can be very regular in certain regions of the brain that are necessary for memory. Another main feature of Alzheimer’s disease is the loss of connections amidst cells. This results in diminished cell operate and necrobiosis.

Vascular dementia is slump in thinking skills caused by conditions that block or reduce flow of blood to the brain, depriving brain cells of vital oxygen and nutrients. Multiple small strokes or other conditions that affect blood vessels and nerve fibres deep inside the brain cause these accumulations to occur. 

  • Track 1-1Alzheimer Disease
  • Track 1-2Vascular Dementia
  • Track 1-3Lewy Body Dementia
  • Track 1-4Mixed Dementia
  • Track 1-5Frontotemporal Dementia
  • Track 1-6Stroke related Dementia
  • Track 1-7Semantic Dementia
  • Track 1-8Normal pressure Hydrocephalus
  • Track 1-9Creutzfeldt-Jakob disease
  • Track 1-10Multi-infarct dementia

Neurodegenerative disease is an allied term for a range of conditions which primarily affect the neurons in the brain and are incurable and attenuate conditions that dynamically result in degeneration or death of nerve cells. Examples of neurodegenerative diseases include Dementia, Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis and Huntington’s disease. The most banal kind of neurodegenerative disorder which people are facing is dementia.

Dementia is a group of conditions characterised by wreckage of at least two brain functions, such as memory loss and judgment. The deficit of brain function is stern enough that an individual cannot do normal activities and leads to such an extent that it interferes with a person’s lifestyle. Additionally, some individuals with dementia cannot manage their emotions. The occurrence of dementia increases emblematically with increasing age. However, it’s not a standard part of aging. Many people live into their 90s beyond with nil signs of dementia.

  • Track 2-1Cognitive Disorders
  • Track 2-2Huntington’s disease
  • Track 2-3Mood Changes
  • Track 2-4Motor Neuron Diseases
  • Track 2-5Memory loss
  • Track 2-6Prion Disease
  • Track 2-7Amyotrophic lateral sclerosis
  • Track 2-8Multiple System Atrophy
  • Track 2-9Corticobasal Degeneration
  • Track 2-10HIV Related Cognitive Impairment
  • Track 2-11Posterior Cortical Atrophy
  • Track 2-12Advances in Research on Neurodegeneration

Amongst the induced and later stages of dementia an individual often involves challenging behavioural problems such as anger, sadness, paranoia, confusion and fear that can further result in oppositional, aggressive and sometimes violent actions.

Although there is currently no cure for dementia and no way to stop the underlying death of brain cells, but dementia research has shown that there is still a leeway to improve the essence of life of people living with dementia by providing a supportive environment to them.  An individual’s centred care is considered important which characterises a clear perceptive of the individual and giving consideration to their cultural background, personal history, social and family networks and preferences for activities in designing their care.

  • Track 3-1Technology for Dementia
  • Track 3-2Dementia Ambient Care
  • Track 3-3Geriatric pharmacotherapy
  • Track 3-4Quality Care Dementia Approach
  • Track 3-5Dementia Care via Telemedicine
  • Track 3-6Dementia Friendly Care Techniques

Diagnosing dementia and Alzheimer is generally difficult, particularly in the initial stages. However diagnosis assessment incorporates medical and patient history to rule out different possible causes. Therefore numerous diagnostic procedures are needed which further includes neurological and physical examination related to blood and urine tests, Mental status assessment to work out the level of mental deterioration, Brain scans (CT Scans and MRI), Caregiver interview to see the level of dependency,  Mini Mental State Examination (MMSE) can also be recommended.

Aside from these diagnostics, dementia patient needs reassurance and support from the people closest to them - including their caregivers, friends and family to help the patient to reminisce their sense of existence and feelings of self-worth.

  • Track 4-1Quality Care
  • Track 4-2Residential Care
  • Track 4-3Supportive environment
  • Track 4-4Palliative Care
  • Track 4-5Art and Dementia
  • Track 4-6Natural Remedies
  • Track 4-7Non-pharmacological Interventions
  • Track 4-8Person-Centred Care Look
  • Track 4-9Social Engagement
  • Track 4-10Memory Care
  • Track 4-11Coping with Caring

Neurological Nursing is a very provoking nursing specialty which deals with assessment, nursing diagnosis, and management of many neurological disorders for which care practitioners provide patient care regarding neurological disorders such as trauma, brain injuries, dementia, stroke, seizures, tumours, headaches, infections and aneurysms, as well as other neurological intricacies.

Talking about dementia, it encircles many different conditions and is apparent by a loss of cognitive abilities affecting attention, memory, linguistics, reasoning and problem-solving skills that interfere with daily activities. It is caused by brain cell deterioration.

Neurological care practitioners commit to give compassionate care to patients suffering from neurological diseases including dementia and Alzheimer, from diagnosis to treatment and beyond.

  • Track 5-1Dementia Nursing
  • Track 5-2Geriatric Nursing
  • Track 5-3Mental Health Nursing
  • Track 5-4Pediatric Nursing
  • Track 5-5Health Care Nursing
  • Track 5-6Cognitive behavioural Therapy and Nursing
  • Track 5-7Dementia Caregivers

Surviving with dementia from conditions such as Alzheimer’s and related disorders can have an ample of emotional, social, psychological and practical impact on a person. Dementia sufferer finds that their mental abilities are declining, for instance, difficulties to remember things, think clearly, communicate with others, or take care of themselves  and often feel vulnerable and need a great deal of reassurance and support.

  • Track 6-1Lack of Sleep
  • Track 6-2Wandering & Aggression
  • Track 6-3Impending medical procedures
  • Track 6-4Routine Disruptions
  • Track 6-5Communication Difficulties
  • Track 6-6Loneliness
  • Track 6-7Overstimulation
  • Track 6-8Pain and Discomfort
  • Track 6-9Finding Support
  • Track 6-10Poor lighting

Neurocognitive disorders accounts a class of mental state disorders that essentially affect learning, memory, judgement, and cognitive behaviour, dementia, and delirium. There's no set age for these disorders to happen but it has been found that age-associated memory impairment and dementia increases typically with increasing age.

Geriatrics  scrutinised and stated that people facing dementia whose symptoms started before the age of 65 are often considered as 'younger people with dementia' or as having young-onset dementia and those before the age of 65 are consider  under   “early onset dementia or “working age dementia” category.

  • Track 7-1Age associated Memory Impairment
  • Track 7-2Normal Forgetfulness vs. Dementia
  • Track 7-3Young Onset Dementia
  • Track 7-4Working Age Dementia
  • Track 7-5Neuroanatomical & Neurochemical changes with ageing
  • Track 7-6Recent Trends in Ageing related Research

Dementia is the case that people over 60 fear the most.  The most common factors which enhances the risk of developing dementia includes ageing, accumulation of  ApoE, Alcohol use, Genetics,  Down syndrome,  Atherosclerosis, Depression,  stroke,  Diabetes,  Hypertension,  Mental illness, smoking,  Unhealthy diet,  Head injuries and many more.

There is no proper cure for dementia; yet medication (including cholinesterase inhibitors containing Donepezil-Rex) and non-drug treatments could give some comfort. However, dementia is not inexorable as we age and there is a lot we can do to dwindle the chances of mellowing it.

  • Track 8-1Depression
  • Track 8-2Accumulation of ApoE
  • Track 8-3Lifestyle Factors
  • Track 8-4Unhealthy Diet
  • Track 8-5Genetics
  • Track 8-6Excessive Alcohol Consumption
  • Track 8-7Head Injuries
  • Track 8-8Metabolic problems & Endocrine abnormalities
  • Track 8-9Reactions to medications
  • Track 8-10Subdural hematomas
  • Track 8-11Normal-pressure hydrocephalus
  • Track 8-12Cardiovascular risk factors

Dementia is not a disease; it’s actually a comprehensive term that portrays a wide range of symptoms related with a drop in memory or thinking skills severe enough to turn down a person's aptitude to perform everyday activities.

No single test can disclose if someone is demented or not however, Doctors or physicians can almost rules out if a person has dementia using medical evaluations which comprises of medical history, mental status testing (Mini-mental state examination, Mini-Cog test) , physical and neurological exams, blood tests and brain imaging (CT Scans and MRI).Though treatment for dementia is entering an energising stage, following many new medications depending upon the pathogenesis of Alzheimer’s illness.

  • Track 9-1Neuroimaging
  • Track 9-2Mental Status testing
  • Track 9-3Brain Imaging
  • Track 9-4Radiology
  • Track 9-5Amyloid and tau imaging
  • Track 9-6Positron Emission Tomography
  • Track 9-7Brain Mapping
  • Track 9-8MR Spectroscopy
  • Track 9-9Biomarker Variables
  • Track 9-10DaT Scan
  • Track 9-11SPECT Scanning
  • Track 9-12Histopathological Tests
  • Track 9-13Structural Brain Imaging
  • Track 9-14Tau- PET Imaging

Dementia is a syndrome with eccentric memory loss and impaired ability to recall events from the past often characterized by Alzheimer's disease. Animal models for dementia or Alzheimer is important to think about the human phenotype and what is being modelled in terms of the animal phenotype. Animal models of Alzheimer’s disease or dementia, based on the genetics of the disease and the closely related front temporal dementia, replicate at least some of the pathology.

Researchers have been successful at modelling very specific aspects of  Alzheimer in the mouse for instance plaques, tangles. Multiple approaches have been adopted to create reliable animal models ranging from rodents to non-human primates, where the animals are exposed to a predetermined injury or causing genetic ablation across specific regions of brain suspected to affect learning functions.

  • Track 10-1Transgenic models
  • Track 10-2Rodent Models
  • Track 10-3Lesion-induced Models
  • Track 10-4Spontaneous models
  • Track 10-5Genetics associated with translational models
  • Track 10-6Translational Research in Dementia
  • Track 10-7Development of anti-dementia drugs
  • Track 10-8Therapeutic Strategies
  • Track 10-9Pathophysiological pathways

Experts believe that biomarkers offer most promising paths to diagnose Alzheimer’s or dementia. A biomarker is something that can reliably indicate the presence of disease.

Certain possible biomarkers are being studied for their strength to indicate initial stages of Dementia or Alzheimer's disease such as including beta-amyloid and tau levels in cerebrospinal fluid (CSF) and brain changes detectable by imaging. However, three biomarkers have been well-established and validated internationally to diagnose AD in CSF with ELISAs: β-amyloid (1–42) [Aβ (1–42)], total tau and phospho-tau-181.

  • Track 11-1Cerebrospinal Fluid Biomarkers
  • Track 11-2Beta-amyloid & tau Biomarkers
  • Track 11-3Blood- Based Biomarkers
  • Track 11-4Neurofilament light protein Biomarkers
  • Track 11-5Tar-DNA binding protein-43
  • Track 11-6Pittsburgh compound B (PIB) Radiotracer
  • Track 11-7Novel approaches in Biomarkers
  • Track 11-8Amyloid Neuroimaging & Biomarkers
  • Track 11-9Morphological AD markers

All cells are like minute factories, producing thousands of proteins with precise functions to keep the cells viable. A flaw can occur if a protein is altered, or if excess or too little is formed. Sometimes, the consequences are so severe that a cell dies. Neuron ruination is the chief cause of dementia and is often associated to malfunctions in the connection system that a neuron needs to survive.

Dementia is associated with accumulation of two proteins – amyloid and tau - into plaques and tangles in the brain. Beta-amyloid accumulates as plaques in Alzheimer's disease or dementia and is an endorsement of the disease. Tau compiles into tangles (known as neurofibrillary tangles or NFT). And further disrupts the structure and communication within the nerve cells, leading to cell death.

  • Track 12-1Amyloid Protein and Dementia
  • Track 12-2Accumulation of toxic amyloid β (Aβ)
  • Track 12-3Neurofibrillary tangles
  • Track 12-4Tau Tangles & Beta Plaques
  • Track 12-5Cerebral amyloid angiopathy
  • Track 12-6Amyloid-beta metabolism
  • Track 12-7Potential Treatments towards Aβ Depositions
  • Track 12-8Disruption of Nerve Cells

Dementia is among the most typical neurodegenerative diseases which specifically arise due to neuron death. It is now becoming evident that neurodegenerative diseases have a biochemical basis. Many neurodegenerative diseases are inherited. Their genes are known and DNA-based diagnosis (including prenatal diagnosis) is available. Loss of neurons is accompanied by specific histopathological findings such as Alzheimer's plaques and Lewy bodies. Some neurodegenerative diseases engage specific anatomical systems or adjoining sets of neurons. 

  • Track 13-1Neuropathological Diagnosis of Dementia
  • Track 13-2Tau Pathology
  • Track 13-3Bio/Histochemical Markers
  • Track 13-4Histopathologic analysis of brain
  • Track 13-5Neuritic Pathology
  • Track 13-6CERAD Behaviour Rating Scale
  • Track 13-7AD Pathology
  • Track 13-8DNA Based Diagnosis
  • Track 13-9Clinical Pathology
  • Track 13-10Advances in Neuropathology of Dementias

Dementia is a common clinical phenomenon; however, management of the coexisting illnesses remains incomplete. Neuropsychiatric turmoil is one of the clinical characteristics of Dementia. Traditionally, this turmoil has been managed with neuroleptics or benzodiazepines but accounts serious side effects. With the advancement in the neuropharmacology field, many new-fangled medications came into existence. Donepezil is a piper dine based reversible, non-competitive cholinesterase inhibitor and proved beneficial for the management of symptoms of Alzheimer’s disease covering dementia, a disease in which cholinergic pathways in the cerebral cortex and basal forebrain are well known to be compromised.

  • Track 14-1Dementia & Pharmacotherapy
  • Track 14-2Memory Drugs
  • Track 14-3Cholinesterase inhibitors
  • Track 14-4Partial NMDA Antagonists
  • Track 14-5Memantine
  • Track 14-6Vitamin E for cognitive changes
  • Track 14-7Immunotherapies
  • Track 14-8Antioxidants
  • Track 14-9Pharmacotherapeutics
  • Track 14-10Neurochemical Pharmacology
  • Track 14-11Recent Trend in Neuropharmacology for Dementia

There are a numerous ways to categorise interventions in dementia care, for instance, by the kind of treatment approach used.  The chief grouping is by the therapeutic goal, with three considerable spheres recommended: the maintenance of function, including cognitive functions, the management of behaviours that challenge and the reduction of comorbid emotional disorders. 

The range of non-pharmacological ‘interventions’ in dementia care is ample and would include the everyday interactions of carers with the person suffering from dementia, the effect of the physical and social conditions and all manner of  ‘therapies’, ranging from art sessions to contact with animals.

  • Track 15-1Nonpharmacological interventions
  • Track 15-2Antipsychotic Therapy & medication
  • Track 15-3Pharmacological alternatives
  • Track 15-4Gene Therapies
  • Track 15-5Allen Cognitive Level Screen
  • Track 15-6Reminiscence therapy
  • Track 15-7Occupational Therapy
  • Track 15-8Physical and cognitive activities